Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-056978
Filing Date
2025-04-23
Accepted
2025-04-23 08:43:49
Documents
17
Period of Report
2025-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A mbx-20250422.htm   iXBRL DEF 14A 890257
2 GRAPHIC img102631631_0.jpg GRAPHIC 264866
3 GRAPHIC img102631631_1.jpg GRAPHIC 7110
4 GRAPHIC img102631631_2.jpg GRAPHIC 264866
5 GRAPHIC img102631631_3.jpg GRAPHIC 482789
6 GRAPHIC img102631631_4.jpg GRAPHIC 183740
  Complete submission text file 0000950170-25-056978.txt   3994923

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mbx-20250422.xsd EX-101.SCH 7918
19 EXTRACTED XBRL INSTANCE DOCUMENT mbx-20250422_htm.xml XML 4099
Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42272 | Film No.: 25859330
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)